Efficacy and Safety of Ocrelizumab in a Treatment-Naive, Early RMS Population: Data over 7 Years from the OPERA OLE Trials

The OPERA I/OPERA II Phase III trials (NCT01247324/NCT01412333) evaluate the efficacy and safety of OCR vs IFN β-1a in patients with RMS. In this pooled OPERA subgroup analysis, the benefits and risks of long-term treatment with OCR as a first-line therapy was examined in a treatment-naive, early RMS subpopulation. Results for disease activity and disability progression are reported over 7 years of treatment in the open-label extension.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.